Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to ...

The failed postpartum depression bill spurs Alabama Medicaid to ease drug approval for new mothers. MONTGOMERY, Ala. — ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- In recognition of Mental Health Awareness Month, PRISM MarketView reaffirms its ...

The product received new approvals in the UK and Brazil in April, further expanding its geographic footprint. ZURZUVAE for postpartum depression generated Q1 sales of $28 million, growing 123% ...

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate of $3.32. Earnings declined 18% year over year on a reported basis, owing ...

Q1 2025 Management View CEO Chris Viehbacher highlighted Biogen's evolving portfolio, with newer products such as LEQEMBI, SKYCLARYS, and ZURZUVAE now comprising 45% of product revenue. He emphasized ...

The fresh start is hallmarked by Alzheimer’s disease med Leqembi, postpartum depression (PPD) treatment Zurzuvae and Friedreich’s ataxia therapy Skyclarys, all of which helped drive Biogen to ...

CEO Barry Greene highlighted a strong start to 2025 with significant milestones for ZURZUVAE, the first oral treatment approved for postpartum depression (PPD). Over 3,000 prescriptions were ...

Cash Equivalents and Marketable Securities: $424 million as of March 31, 2025. ZURZUVAE Prescriptions: Greater than 3,000 prescriptions in Q1 2025, a 22% increase from Q4 2024. Prescriber Trends ...

Cash Equivalents and Marketable Securities: $424 million as of March 31, 2025. ZURZUVAE Prescriptions: Greater than 3,000 prescriptions in Q1 2025, a 22% increase from Q4 2024. Prescriber Trends: ...